Q-omics provides the consensus-scored MSGN1 profile across patient tissues and cancer cell-line models. MSGN1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MSGN1 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, MSGN1 RNA expression shows 9,544 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, LUSC, and TGCT as cancer lineages where MSGN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSGN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSGN1 survival associations across molecular data types. MSGN1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSGN1 RNA expression–survival associations across cancer types. High MSGN1 expression shows unfavorable associations in LIHC, SCLC and KICH, but favorable associations in HNSC, LUSC and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MSGN1 RNA expression.
This table summarizes MSGN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MSGN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSGN1 shows lower tumor expression in PRAD and STAD and higher tumor expression in LUSC, HNSC and THCA. The LUSC box plot shows higher MSGN1 RNA expression in tumor versus normal tissue (log2 FC = +1.023, t-test p < 0.001).
This table shows molecular features associated with MSGN1 in patient tissues and cancer cell lines. In patient samples, MSGN1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MSGN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
